Pharmaceutical Products Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1NEUP Neuphoria Therapeutics
1.26 K
 0.12 
 6.13 
 0.71 
2ACOG Alpha Cognition Common
445.52
 0.05 
 3.85 
 0.19 
3HURA TuHURA Biosciences
106.4
 0.00 
 9.14 
 0.03 
4AAPG Ascentage Pharma Group
60.58
 0.06 
 3.19 
 0.18 
5MNPR Monopar Therapeutics
47.0
 0.13 
 8.25 
 1.06 
6MRSN Mersana Therapeutics
32.03
(0.18)
 8.67 
(1.55)
7MBIO Mustang Bio
31.75
(0.29)
 9.18 
(2.62)
8DRRX Durect
21.63
(0.05)
 3.99 
(0.19)
9TLX Telix Pharmaceuticals Limited
20.71
 0.10 
 3.22 
 0.32 
10MBOT Microbot Medical
14.51
 0.09 
 14.41 
 1.34 
11MDCX Medicus Pharma Ltd
12.91
 0.09 
 8.56 
 0.79 
12DYAI Dyadic International
11.53
(0.14)
 4.09 
(0.56)
13MDGL Madrigal Pharmaceuticals
10.14
 0.05 
 4.32 
 0.20 
14MIRM Mirum Pharmaceuticals
10.05
 0.08 
 2.54 
 0.21 
15MGTX MeiraGTx Holdings PLC
9.06
 0.10 
 4.96 
 0.49 
16MCRB Seres Therapeutics
9.02
(0.04)
 5.25 
(0.20)
17DWTX Dogwood Therapeutics,
8.6
 0.12 
 51.41 
 6.06 
18MIST Milestone Pharmaceuticals
8.16
 0.01 
 5.40 
 0.03 
19VCEL Vericel Corp Ord
7.97
(0.12)
 2.58 
(0.32)
20DRUG Bright Minds Biosciences
6.28
(0.01)
 5.13 
(0.06)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.